Skip to main content
. 2024 Dec 31;17:132. doi: 10.1186/s13045-024-01651-5

Table 2.

Safety overview

n, % Ia escalation Ib escalation Ib expansion
n = 28 n = 45 sqNSCLC, n = 20 GC, n = 17
TRAEs 19 (67.9) 34 (75.6) 20 (100) 17 (100)
TRAEs, Grade ≥ 3 6 (21.4) 10 (22.2) 16 (80) 11 (64.7)
TRSAEs 4 (14.3) 5 (11.1) 5 (25) 7 (41.2)
TRAEs leading to dose interruption 2 (7.1) 6 (13.3) 8 (40) 14 (82.4)
TRAEs leading to treatment discontinuation 1 (3.6) 0 4 (20) 6 (35.3)
TRAEs leading to death 0 0 0 0
irAEs 3 (10.7) 14 (31.1) 14 (70) 10 (58.8)
irAEs, Grade ≥ 3 1 (3.6) 3 (6.7) 4 (20) 3 (17.6)